Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGENT 797

Next Previous
Drug Profile

AGENT 797

Alternative Names: AGENT-797; Allogeneic iNKT cell therapies - Agenus; Unmodified iNKT cell therapies - Agenus

Latest Information Update: 30 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; MiNK Therapeutics
  • Class Antineoplastics; Antivirals; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Solid tumours
  • Phase I/II SARS-CoV-2 acute respiratory disease
  • Phase I Graft-versus-host disease; Multiple myeloma

Most Recent Events

  • 24 Apr 2026 Agenus plans a phase-II trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV), (NCT07550088)
  • 20 Apr 2026 Efficacy and adverse event data from a phase II trial in Adenocarcinoma released by Agenus
  • 31 Mar 2026 ImmunityBio plans a phase II trial for Community-acquired pneumonia (Combination therapy) (SC, Injection) in the first half of 2026 (NCT07492888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top